ClinVar Miner

Submissions for variant NM_000518.5(HBB):c.151A>T (p.Thr51Ser)

gnomAD frequency: 0.00002  dbSNP: rs63750336
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000586865 SCV000697086 uncertain significance not specified 2020-07-07 criteria provided, single submitter clinical testing Variant summary: HBB c.151A>T (p.Thr51Ser) results in a conservative amino acid change located in the Globin domain (IPR000971) of the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 251426 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.151A>T has been reported in the literature in a hematologically asymptomatic individual (Kleinert_2008) and among the abnormal hemoglobin variants identified in a thalassemia screening cohort study (example, Zhang_2019). These reports do not provide unequivocal conclusions about association of the variant with Hemoglobinopathy. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One internal specimen analyzed at our laboratory carried this variant in addition to two other pathogenic HBB variants (c.316-197C>T, and c.79G>A, HbE), however, the phase of this variant was not analyzed. This finding is suggestive of an unlikely association with disease. No other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as VUS-possibly benign.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV003478322 SCV004219860 uncertain significance not provided 2022-11-15 criteria provided, single submitter clinical testing The HBB c.151A>T (p.Thr51Ser) variant, also known as Hb Zurich-Langstrasse, is described as having normal stability. The frequency of this variant in the general population is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in a heterozygous asymptomatic individual (PMID: 17932132 (2008)). Additionally, the variant has been identified in individuals and neonates during large beta thalassemia screening studies in the Chinese population (PMIDs: 30809867 (2019) and 33439495 (2021)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is deleterious or benign. Taking into account the available information, we are unable to determine the clinical significance of this variant.
Natera, Inc. RCV001272127 SCV001453780 uncertain significance beta Thalassemia 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.